-+ 0.00%
-+ 0.00%
-+ 0.00%

Autolus Therapeutics Reports 42.6-Month Median Response From FELIX Study, Showing Obe-Cel's Potential For Long-Term Remission In r/r B-ALL

Benzinga·06/12/2025 07:33:35
Listen to the news
  • Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up
  • More than half of patients still in remission at 24 months
  • 38% of ongoing responders did not receive any subsequent therapy by month 33
  • Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel